$NBIO - Nascent is committed to changing patient expectations and outcomes in one of the world's most debilitating cancers and Sharp is a valuable partner towards achieving this goal. We're highly encouraged by the potential of Pritumumab...
https://finance.yahoo.com/news/laurel-amtower...00566.html